New Real-World Data Supports Use of Antiviral Therapy for Patients Hospitalized With COVID-19
Gilead’s Veklury (remdesivir), a nucleotide analog prodrug, was associated with lower risk of developing long-COVID.
Gilead Sciences has announced new data from three real-world retrospective studies involving its antiviral therapy for patients hospitalized with COVID-19, Veklury (remdesivir), according to a press release.1
To further explore the efficacy of Veklury and its potential impact on the risk of long-COVID, Gilead analyzed HealthVerity data from 52,006 patients. Results from the study showed that Veklury use was associated with a 10% lower risk of any post-COVID conditions (PCC) across multiple age groups.
In the second study, data from the PINC AI Healthcare database from the Omicron era (December 2021 – April 2023) showed an association between Veklury use and reduced mortality among immunocompromised people in the study who were hospitalized for COVID-19. The study included 10,687 immunocompromised patients who received Veklury and 4,989 who were matched controls. At day 28, those who were immunocompromised and treated with Veklury showed an overall 25% lower mortality risk compared to the non-Veklury group.
The third real-world study matched 33,037 patients who received both Veklury and dexamethasone to 33,037 patients who received only dexamethasone. Data showed improved outcomes in those receiving the dual therapy.
“The real-world data presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI) continue to reinforce the strong efficacy and safety profile of Veklury, as well as the potential benefit of Veklury for people affected by COVID-19,” said Frank Duff, MD, senior vice president, virology therapeutic area head, Gilead Sciences in the press release. “As we enter the fourth year of COVID-19, Veklury remains the antiviral standard of care for people hospitalized for COVID-19. These latest data add to our scientific understanding about Veklury’s potential role in reducing mortality, including in immunocompromised people, and helping to reduce the risk of getting long-COVID symptoms.”
Reference
- New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19. News release. March 5, 2024. Accessed March 6, 2024. https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/new-realworld-data-further-support-the-use-of-veklury-remdesivir-for-people-hospitalized-with-covid19
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
Tirzepatide Reduces Heart Failure Risk, Improves Physical Function in HFpEF Patients
November 18th 2024The Phase III SUMMIT trial showed that tirzepatide significantly reduces the risk of worsening heart failure events or death from cardiovascular causes, enhances physical function, and leads to weight loss and reduced inflammation in patients with heart failure with preserved ejection fraction.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.
